Validation of the Neuropathy Impairment Score (NIS) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy

Cover Page

Cite item

Full Text

Abstract

Background. A clinical application of scales and questionnaires is essential for the objective evaluation of treatment response, disease course, quality of life and the disability level in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). Neuropathy Impairment Score (NIS) has become widespread in epidemiological and clinical studies of various polyneuropathies, including CIDP. However, its application in Russia is limited by the absence of its validated version for Russian-speaking patients. Aim. To develop the Russian validated version of the NIS for its application in patients with CIDP. Materials and methods. The study involved 50 patients with CIDP (25 with multifocal variant of CIDP (Lewis–Sumner syndrome) and 25 with typical CIDP). The validation process included two stages: translation and linguocultural ratification of the scale according to the standard protocol and an assessment of its psychometric properties, such as reliability, validity and sensitivity. Results. The developed Russian version of the NIS demonstrated the high level of reliability, sensitivity and validity. Conclusion. The validated Russian version of the NIS can be recommended for application in research and clinical practice.

About the authors

N. A. Suponeva

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0003-3956-6362

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

A. S. Arestova

Research Center of Neurology

Author for correspondence.
Email: fake@neicon.ru
ORCID iD: 0000-0002-9890-3552

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

E. A. Melnik

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0001-5436-836X

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

A. A. Zimin

Research Center of Neurology; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia

Email: fake@neicon.ru
ORCID iD: 0000-0002-9226-2870

 80 Volokolamskoe Shosse, Моscow 125367 

 1 Ostrovityanova St., Moscow 117513 

Russian Federation

A. M. Narbut

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0003-2026-5199

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

A. Yakubu

Columbia University

Email: fake@neicon.ru
ORCID iD: 0000-0001-5434-4966

116th Street and Broadway, New York 10027 

United States

E. S. Sherbakova

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0002-1706-089X

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

A. B. Zaytsev

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)

Email: fake@neicon.ru
ORCID iD: 0000-0003-3774-3070

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

D. A. Grishina

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0002-7924-3405

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

D. G. Yusupova

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0002-5826-9112

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

E. V. Gnedovskaya

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0001-6026-3388

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

M. A. Piradov

Research Center of Neurology

Email: fake@neicon.ru
ORCID iD: 0000-0002-6338-0392

 80 Volokolamskoe Shosse, Моscow 125367 

Russian Federation

References

  1. Broers M.C., Bunschoten C., Nieboer D. et al. Incidence and prevalence of chronic inflammatory demyelinating polyradiculoneuropathy: A systematic review and meta-analysis. Neuroepidemiology 2019;52(3–4):161–72. doi: 10.1159/000494291
  2. Kieseier B.C., Mathey E.K., Sommer C. et al. Immune-mediated neuropathies. Nat Rev Dis Primers 2018;4(1):31. doi: 10.1038/s41572-018-0027-2
  3. Van den Bergh P.Y.K., van Doorn P.A., Hadden R.D.M. et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision. J Peripher Nerv Syst 2021;26(3):242–68. doi: 10.1111/jns.12455
  4. Oaklander A.L., Lunn M.P., Hughes R.A. et al. Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): An overview of systematic reviews. Cochrane Database Syst Rev 2017;13;1(1):CD010369. doi: 10.1002/14651858.CD010369.pub2
  5. Stino A.M., Naddaf E., Dyck P.J. et al. Chronic inflammatory demyelinating polyradiculoneuropathy – Diagnostic pitfalls and treatment approach. Muscle Nerve 2021;63(2):157–69. doi: 10.1002/mus.27046
  6. Fisse A.L., Motte J., Grüter T. et al. Comprehensive approaches for diagnosis, monitoring and treatment of chronic inflammatory demyelinating polyneuropathy. Neurol Res Pract 2020;2:42. doi: 10.1186/s42466-020-00088-8
  7. Arestova А. S., Melnik Е. А., Zaytsev A. B. et al. Inflammatory Neuropathy Cause and Treatment (INCAT) Scale for the assessment of disability level in patients with chronic inflammatory demyelinating polyneuropathy: linguocultural ratification in Russia. Nervno-myshechnye bolezni = Neuromuscular Diseases 2021;11(4):26–33. (In Russ.). doi: 10.17650/2222-8721-2021-11-4-26-33
  8. Suponeva N.A., Arestova А.S., Melnik Е.А. et al. Validation of the Medical Research Council sum score (MRCss) for use in Russian-speaking patients with chronic inflammatory demyelinating polyneuropathy. Nervno-myshechnye bolezni = Neuromuscular Diseases 2023;13(1):68–74. (In Russ.). doi: 10.17650/2222-8721-2023-13-1-68-74
  9. Van Nes S.I., Vanhoutte E.K., van Doorn P.A. et al. Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 2011;76(4):337–45. doi: 10.1212/WNL.0b013e318208824b
  10. Dyck P.J., Sherman W.R., Hallcher L.M. et al. Human diabetic endoneurial sorbitol, fructose, and myo-inosirol related to sural nerve morphomerry. Ann Neurol 1980;8:590–6.
  11. Dyck P.J., Boes C.J., Mulder D. et al. History of standard scoring, notation, and summation of neuromuscular signs. A current survey and recommendation. J Peripher Nerv Syst 2005;10(2):158–73. doi: 10.1111/j.1085-9489.2005.0010206.x
  12. Dyck P.J., Litchy W.J., Kratz K.M. et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838–45.
  13. Dyck P.J., Daube J., OʼBrien P. et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461–5.
  14. Dyck P.J., Taylor B.V., Davies J.L. et al. Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Muscle Nerve 2015;52(4):488–97. doi: 10.1002/mus.24707
  15. Benson M.D., Waddington-Cruz M., Berk J.L. et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018;5;379(1):22–31. doi: 10.1056/NEJMoa1716793
  16. Dyck P.J.B., González-Duarte A., Obici L. et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7. J Neurol Sci 2019;15(405):116424. doi: 10.1016/j.jns.2019.116424
  17. Hsieh R.Y., Huang I.C., Chen C. et al. Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: A meta-analysis and systematic review. Nutrients 2023;18;15(16):3634. doi: 10.3390/nu15163634
  18. Baicus C., Purcarea A., von Elm E. et al. Alpha-lipoic acid for diabetic peripheral neuropathy. Cochrane Database Syst Rev 2024;11;1(1):CD012967. doi: 10.1002/14651858
  19. Mokkink L.B., Prinsen C.A., Bouter L.M et al. The Consensusbased Standards for the Selection of Health Measurement Instruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 2016;19;20(2):105–13. doi: 10.1590/bjpt-rbf.2014.0143
  20. Beaton D., Bombardier C., Guillemin F. et al. Recommendations for the cross-cultural adaptation of health status measures. New York: American Academy of Orthopaedic Surgeons, 2002. Pp. 1–9.
  21. Serdar C.C., Cihan M., Yücel D. et al. Sample size, power and effect size revisited: Simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb) 2021;31:010502. doi: 10.11613/BM.2021.010502
  22. Shastri A., Al Aiyan A., Kishore U. et al. Immune-mediated neuropathies: Pathophysiology and management. Int J Mol Sci 2023;14;24(8):7288. doi: 10.3390/ijms24087288
  23. Doneddu P.E., Dentoni M., Nobile-Orazio E. Atypical chronic inflammatory demyelinating polyradiculoneuropathy: Recent advances on classification, diagnosis, and pathogenesis. Curr Opin Neurol 2021;1;34(5):613–24. doi: 10.1097/WCO.0000000000000979
  24. Draak T.H., Vanhoutte E.K., van Nes S.I. et al. Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses. J Peripher Nerv Syst 2015;20(3):277–88. doi: 10.1111/jns.12127

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 85909 от  25.08.2023.